EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1247	(514/303,546/118).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/10/12 07:34
L2	353	l1 and imidazo	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/10/12 07:34
L3	198	l2 and pyridin	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/10/12 07:35
L4	194	l3 and NO	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/10/12 07:35
L5	26	l4 and synthase	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/10/12 07:35

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/CAplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	BEILSTEIN updated with new compounds
NEWS 12	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 13	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 14	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 15	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 16	AUG 27	USPATOLD now available on STN
NEWS 17	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 18	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 19	SEP 13	FORIS renamed to SOFIS
NEWS 20	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 21	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 22	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 23	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 24	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:37:29 ON 12 OCT 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 07:37:34 ON 12 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 10 OCT 2007 HIGHEST RN 950149-06-1
DICTIONARY FILE UPDATES: 10 OCT 2007 HIGHEST RN 950149-06-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10573203.str





chain nodes :
10 11 18 19 21 22 23 24 25 26 28
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17
chain bonds :
8-10 9-19 10-11 10-26 11-12 11-21 11-22 13-25 14-18 15-24 16-23 18-28
ring bonds :
1-2 1-6 2-3 3-4 3-7 4-5 4-9 5-6 7-8 8-9 12-13 12-17 13-14 14-15 15-16
16-17
exact/norm bonds :
3-7 4-9 7-8 8-9 10-26 14-18 18-28
exact bonds :
8-10 9-19 10-11 11-12 11-21 11-22 13-25 15-24 16-23
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17
isolated ring systems :
containing 1 : 12 :

G1:C,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 28:CLASS

```
L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
G1 C,H


Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 07:37:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       13 TO ITERATE

100.0% PROCESSED       13 ITERATIONS                                5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           44 TO      476
PROJECTED ANSWERS:               5 TO      234

L2            5 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 07:37:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      256 TO ITERATE

100.0% PROCESSED      256 ITERATIONS                              133 ANSWERS
SEARCH TIME: 00.00.01

L3          133 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             172.10     172.31
```

FILE 'CAPLUS' ENTERED AT 07:38:01 ON 12 OCT 2007

FILE COVERS 1907 - 12 Oct 2007 VOL 147 ISS 17
FILE LAST UPDATED: 11 Oct 2007 (20071011/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4 7 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:341554 CAPLUS
DOCUMENT NUMBER: 144:381708
TITLE: In vivo characterization of the novel imidazopyridine BYK191023 [2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine], a potent and highly selective inhibitor of inducible nitric-oxide synthase
AUTHOR(S): Lehner, Martin D.; Marx, Degenhard; Boer, Rainer; Strub, Andreas; Hesslinger, Christian; Eltze, Manfrid; Ulrich, Wolf-Ruediger; Schwoebel, Frank; Schermuly, Ralph Theo; Barsig, Johannes
CORPORATE SOURCE: Department of Pharmacology, ALTANA Pharma AG, Konstanz, Germany
SOURCE: Journal of Pharmacology and Experimental Therapeutics (2006), 317(1), 181-187
CODEN: JPETAB; ISSN: 0022-3565
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Excessive release of nitric oxide from inducible nitric-oxide synthase (iNOS) has been postulated to contribute to pathol. in a number of inflammatory diseases. We recently identified imidazopyridine derivs. as a novel class of potent nitric-oxide synthase inhibitors with high selectivity for the inducible isoform. In the present study, we tested the in vivo potency of BYK191023 [2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine], a selected member of this inhibitor class, in three different rat models of lipopolysaccharide-induced systemic inflammation. Delayed administration of BYK191023 dose-dependently suppressed the lipopolysaccharide-induced increase in plasma nitrate/nitrite (NOx) levels with an ED50 of 14.9 μmol/kg/h. In a model of systemic hypotension following high-dose lipopolysaccharide challenge, curative administration of BYK191023 at a dose that inhibited 83% of the NOx increase completely prevented the gradual decrease in mean

arterial blood pressure observed in vehicle-treated control animals. The vasopressor effect was specific for endotoxemic animals since BYK191023 did not affect blood pressure in saline-challenged controls. In addition, in a model of lipopolysaccharide-induced vascular hyporesponsiveness, BYK191023 infusion partially restored normal blood pressure responses to norepinephrine and sodium nitroprusside via an L-arginine competitive mechanism. Taken together, BYK191023 is a member of a novel class of highly isoform-selective iNOS inhibitors with promising in vivo activity suitable for mechanistic studies on the role of selective iNOS inhibition as well as clin. development.

IT 608880-48-4, BYK191023
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in vivo characterization of inducible nitric-oxide synthase inhibitor imidazopyridine BYK191023)

RN 608880-48-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:43156 CAPLUS

DOCUMENT NUMBER: 144:163527

TITLE: The novel imidazopyridine 2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) is a highly selective inhibitor of the inducible nitric-oxide synthase

AUTHOR(S): Strub, Andreas; Ulrich, Wolf-Ruediger; Hesslinger, Christian; Eltze, Manfrid; Fuchss, Thomas; Strassner, Jochen; Strand, Susanne; Lehner, Martin D.; Boer, Rainer

CORPORATE SOURCE: Departments of Biochemistry, Chemistry and Pharmacology, ALTANA Pharma AG, Konstanz, Germany

SOURCE: Molecular Pharmacology (2006), 69(1), 328-337
CODEN: MOPMA3; ISSN: 0026-895X

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We have identified imidazopyridine derivs. as a novel class of NO synthase inhibitors with high selectivity for the inducible isoform. 2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) showed half-maximal inhibition of crudely purified human inducible (iNOS), neuronal (nNOS), and endothelial (eNOS) NO synthases at 86 nM, 17 μM, and 162 μM, resp. Inhibition of inducible NO synthase was competitive with L-arginine, pointing to an interaction of BYK191023 with the catalytic center of the enzyme. In radioligand and surface plasmon resonance expts., BYK191023 exhibited an affinity for iNOS, nNOS, and eNOS of 450 nM, 30 μM, and >500 μM, resp. Inhibition of cellular nitrate/nitrite synthesis in RAW, rat mesangium, and human embryonic kidney 293 cells after iNOS induction showed 40- to 100-fold higher IC50 values than at the isolated enzyme, in agreement with the much higher L-arginine concns. in cell culture media and inside intact cells. BYK191023 did not show any toxicity in various rodent and human cell lines

up to high micromolar concns. The inhibitory potency of BYK191023 was tested in isolated organ models of iNOS (lipopolysaccharide-treated and phenylephrine-precontracted rat aorta; IC50 = 7 μM), eNOS (arecaidine propargyl ester-induced relaxation of phenylephrine-precontracted rat aorta; IC50 > 100 μM), and nNOS (field-stimulated relaxation of phenylephrine-precontracted rabbit corpus cavernosum; IC50 > 100 μM). These data confirm the high selectivity of BYK191023 for iNOS over eNOS and nNOS found at isolated enzymes. In summary, we have identified a new highly selective iNOS inhibitor structurally unrelated to known compds. and L-arginine. BYK191023 is a valuable tool for the investigation of iNOS-mediated effects in vitro and in vivo.

IT 608880-48-4, BYK 191023
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(structure activity relationship studied of imidazopyridine compds. as selective inhibitors of nitric-oxide synthase isoforms)

RN 608880-48-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:300447 CAPLUS
DOCUMENT NUMBER: 142:373838
TITLE: Preparation of imidazopyridine derivatives as inducible NO-synthase inhibitors
INVENTOR(S): Fuchss, Thomas; Martin, Thomas; Boer, Rainer; Strub, Andreas; Eltze, Manfrid; Lehner, Martin; Ulrich, Wolf-Ruediger
PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030771	A1	20050407	WO 2004-EP52378	20040930
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004276015	A1	20050407	AU 2004-276015	20040930
CA 2540083	A1	20050407	CA 2004-2540083	20040930
EP 1675854	A1	20060705	EP 2004-787263	20040930

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

CN 1856491	A	20061101	CN 2004-80027592		20040930
BR 2004014972	A	20061107	BR 2004-14972		20040930
JP 2007507467	T	20070329	JP 2006-530264		20040930
NO 2006001344	A	20060324	NO 2006-1344		20060324
MX 2006PA03349	A	20060608	MX 2006-PA3349		20060324
US 2007043073	A1	20070222	US 2006-573484		20060324
IN 2006MN00475	A	20070316	IN 2006-MN475		20060424
PRIORITY APPLN. INFO.:			EP 2003-22053	A	20031001
			WO 2004-EP52378	W	20040930

OTHER SOURCE(S): CASREACT 142:373838; MARPAT 142:373838

GI



I



II

AB Title compds. I [R1 = H, alkyl; R2 = H, alkyl; R3 = H, halo; R4 = H, halo, alkyl, alkoxy; R5 = alkyl; A = alkylene] and their resp. pharmaceutically acceptable salts, are prepared and disclosed as inducible no-synthase inhibitors. Thus, e.g., II was prepared via Suzuki coupling of 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine (preparation given) with N,N-dimethyl-4-bromobenzenesulfonamide. The activity of I towards inducible NO-synthase was evaluated in inhibition assays and revealed -logIC50 values in the range of 7.45 up to 7.86 mol/L. I as inducible NO-synthase inhibitors should prove useful in the treatment of acute and chronic inflammatory diseases.

IT 849357-47-7P 849357-48-8P 849357-49-9P
849357-50-2P 849357-51-3P 849357-52-4P
849357-54-6P 849357-55-7P 849357-56-8P
849357-57-9P 849357-58-0P 849357-59-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyridine derivs. as inducible NO-synthase inhibitors)

RN 849357-47-7 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-

b]pyridin-6-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 849357-48-8 CAPLUS
CN Benzenesulfonamide, N,N-diethyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849357-49-9 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 849357-50-2 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849357-51-3 CAPLUS
CN Benzenesulfonamide, N-ethyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849357-52-4 CAPLUS
CN Benzenesulfonamide, 2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 849357-54-6 CAPLUS
CN Benzenesulfonamide, 2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849357-55-7 CAPLUS
CN Benzenesulfonamide, 2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 849357-56-8 CAPLUS
CN Benzenesulfonamide, N-ethyl-2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849357-57-9 CAPLUS
CN Benzenesulfonamide, N-ethyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 849357-58-0 CAPLUS
CN Benzenesulfonamide, N,N-diethyl-2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849357-59-1 CAPLUS
CN Benzenesulfonamide, N-ethyl-2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)



IT 608880-54-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazopyridine derivs. as inducible NO-synthase inhibitors)
RN 608880-54-2 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 6-iodo-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:300446 CAPLUS
DOCUMENT NUMBER: 142:373837
TITLE: Preparation of imidazopyridine derivatives as inducible NO-synthase inhibitors
INVENTOR(S): Fuchss, Thomas; Martin, Thomas; Boer, Rainer; Strub, Andreas; Eltze, Manfrid; Lehner, Martin; Ulrich, Wolf-Ruediger
PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030770	A1	20050407	WO 2004-EP52377	20040930
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004276014	A1	20050407	AU 2004-276014	20040930
CA 2540243	A1	20050407	CA 2004-2540243	20040930
EP 1670796	A1	20060621	EP 2004-787262	20040930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1856495	A	20061101	CN 2004-80027833	20040930
BR 2004014933	A	20061107	BR 2004-14933	20040930
JP 2007507466	T	20070329	JP 2006-530263	20040930
NO 2006001317	A	20060323	NO 2006-1317	20060323
MX 2006PA03351	A	20060608	MX 2006-PA3351	20060324
US 2006293302	A1	20061228	US 2006-573202	20060324
US 7279488	B2	20071009		
IN 2006MN00362	A	20070615	IN 2006-MN362	20060331
PRIORITY APPLN. INFO.:			EP 2003-22046 A	20031001
			WO 2004-EP52377 W	20040930

OTHER SOURCE(S): CASREACT 142:373837; MARPAT 142:373837
GI



I



II

AB Title compds. I [R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkoxyalkyl, hydroxyalkyl, etc.; R3 = alkyl, CF3, completely or predominantly F-substituted alkoxy, etc.; R1 and R2 together = (un)saturated-, (un)substituted-nitrogen heterocycle; R4 = H, halo, alkyl, alkoxy; R5 = alkyl; A = alkylene] and their resp. pharmaceutically acceptable salts, are prepared and disclosed as inducible no-synthase inhibitors. Thus, e.g., II was prepared via Suzuki coupling of 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine (preparation given) with 1-(4-bromo-benzene-sulfonyl)-4-methyl-piperazine. The activity of I towards inducible NO-synthase was evaluated in inhibition assays and revealed -logIC50 values in the range of 6.51 up to 7.89 mol/L. I as inducible NO-synthase inhibitors should prove useful in the treatment of acute and chronic inflammatory diseases.

IT 849530-66-1P 849530-68-3P 849530-70-7P
849530-72-9P 849530-74-1P 849530-76-3P
849530-78-5P 849530-80-9P 849530-82-1P
849530-84-3P 849530-86-5P 849530-88-7P
849530-90-1P 849530-92-3P 849530-94-5P
849530-96-7P 849530-98-9P 849531-00-6P
849531-02-8P 849531-04-0P 849531-06-2P
849531-08-4P 849531-10-8P 849531-12-0P
849531-14-2P 849531-16-4P 849531-18-6P
849531-20-0P 849531-23-3P 849531-25-5P
849531-27-7P 849531-29-9P 849531-31-3P
849531-33-5P 849531-36-8P 849531-38-0P
849531-40-4P 849531-42-6P 849531-44-8P
849531-46-0P 849531-48-2P 849531-50-6P
849531-52-8P 849531-54-0P 849531-56-2P
849531-58-4P 849531-60-8P 849531-62-0P
849531-64-2P 849531-66-4P 849531-68-6P
849531-70-0P 849531-72-2P 849531-74-4P
849531-76-6P 849531-78-8P 849531-80-2P
849531-82-4P 849531-84-6P 849531-86-8P
849531-88-0P 849531-90-4P 849531-92-6P
849531-94-8P 849531-96-0P 849531-98-2P
849532-00-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyridine derivs. as inducible NO-synthase inhibitors)

RN 849530-66-1 CAPLUS
CN Piperazine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 849530-68-3 CAPLUS
CN Piperazine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 849530-70-7 CAPLUS
CN Piperazine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 849530-72-9 CAPLUS
CN Piperazine, 1-(4-cyanophenyl)-4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 849530-74-1 CAPLUS
CN Piperazine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 849530-76-3 CAPLUS
CN Piperazine, 1-(2,4-dimethylphenyl)-4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 849530-78-5 CAPLUS
CN Piperazine, 1-(3,5-dichlorophenyl)-4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 849530-80-9 CAPLUS
CN Piperazine, 1-(2-methoxyethyl)-4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 849530-82-1 CAPLUS
CN Piperazine, 1-acetyl-4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 849530-84-3 CAPLUS
CN Morpholine, 4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 849530-86-5 CAPLUS
CN 1H-1,4-Diazepine, hexahydro-1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 849530-88-7 CAPLUS
CN Piperidine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 849530-90-1 CAPLUS
CN Piperidine, 4-benzoyl-1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 849530-92-3 CAPLUS
CN 1,4-Dioxa-8-azaspiro[4.5]decane, 8-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 849530-94-5 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 849530-96-7 CAPLUS
CN 5H-1,4-Diazepin-5-one, hexahydro-1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 849530-98-9 CAPLUS
CN Benzenesulfonamide, N-(2-hydroxyethyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849531-00-6 CAPLUS
CN Benzenesulfonamide, N,N-bis(2-hydroxyethyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849531-02-8 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 849531-04-0 CAPLUS
CN Benzenesulfonamide, N-cyclohexyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849531-06-2 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N,N-dimethyl-2-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 849531-08-4 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N,N-dimethyl-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 849531-10-8 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N,N,3-trimethyl- (9CI) (CA INDEX NAME)



RN 849531-12-0 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 849531-14-2 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 849531-16-4 CAPLUS
CN Benzenesulfonamide, N-(2-methoxyphenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849531-18-6 CAPLUS
CN Benzenesulfonamide, N-[4-(dimethylamino)phenyl]-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849531-20-0 CAPLUS
CN Benzenesulfonamide, N-(4-chlorophenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 849531-23-3 CAPLUS
CN Piperazine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 849531-25-5 CAPLUS
CN Piperazine, 1-ethyl-4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 849531-27-7 CAPLUS
CN Piperazine, 1-(2,6-dimethylphenyl)-4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 849531-29-9 CAPLUS
CN Piperazine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 849531-31-3 CAPLUS
CN Piperazine, 1-[[3-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 849531-33-5 CAPLUS
CN Piperidine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 849531-36-8 CAPLUS
CN Piperazine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-2-(trifluoromethoxy)phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 849531-38-0 CAPLUS
CN Isoquinoline, 6,7-diethoxy-1,2,3,4-tetrahydro-2-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 849531-40-4 CAPLUS
CN Piperazine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-2-(trifluoromethyl)phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 849531-42-6 CAPLUS
CN Piperazine, 1-[[2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 849531-44-8 CAPLUS
CN Piperazine, 1-[[2-chloro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 849531-46-0 CAPLUS
CN Piperazine, 1-[[3-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 849531-48-2 CAPLUS
CN 5H-1,4-Diazepin-5-one, hexahydro-1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 849531-50-6 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl-N-phenyl- (9CI) (CA INDEX NAME)



RN 849531-52-8 CAPLUS
CN Piperazine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-3-methylphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 849531-54-0 CAPLUS
CN 5H-1,4-Diazepin-5-one, hexahydro-1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 849531-56-2 CAPLUS
CN 5H-1,4-Diazepin-5-one, 4-ethylhexahydro-1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 849531-58-4 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 849531-60-8 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 849531-62-0 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 849531-64-2 CAPLUS
CN Benzenesulfonamide, N-[4-(dimethylamino)phenyl]-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 849531-66-4 CAPLUS
CN Benzenesulfonamide, N-(2-fluoro-4-methylphenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849531-68-6 CAPLUS
CN Benzenesulfonamide, N-(4-methoxyphenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849531-70-0 CAPLUS
CN Benzenesulfonamide, N-(4-methoxyphenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 849531-72-2 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 849531-74-4 CAPLUS
CN Benzenesulfonamide, N-(4-chlorophenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849531-76-6 CAPLUS
CN Pyrrolidine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 849531-78-8 CAPLUS
CN Azetidine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 849531-80-2 CAPLUS
CN Benzenesulfonamide, N,N-bis(2-methoxyethyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849531-82-4 CAPLUS
CN Benzenesulfonamide, N-cyclobutyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849531-84-6 CAPLUS
CN Benzenesulfonamide, N-cyclopropyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849531-86-8 CAPLUS
CN Pyrrolidine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-7-methyl-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 849531-88-0 CAPLUS
CN Piperidine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-7-methyl-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 849531-90-4 CAPLUS
CN Morpholine, 4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-7-methyl-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 849531-92-6 CAPLUS
CN Azetidine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-7-methyl-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 849531-94-8 CAPLUS
CN Thiomorpholine, 4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 849531-96-0 CAPLUS
CN Thiomorpholine, 4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-, 1-oxide (9CI) (CA INDEX NAME)



RN 849531-98-2 CAPLUS
CN Thiomorpholine, 4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 849532-00-9 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-2-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



IT 608880-54-2P, 2-[2-[4-Methoxypyridin-2-yl]ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazopyridine derivs. as inducible NO-synthase inhibitors)
RN 608880-54-2 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 6-iodo-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:300445 CAPLUS
DOCUMENT NUMBER: 142:373836
TITLE: Preparation of imidazopyridine derivatives as inducible NO-synthase inhibitors
INVENTOR(S): Fuchss, Thomas; Martin, Thomas; Boer, Rainer; Strub, Andreas; Eltze, Manfrid; Lehner, Martin; Marx, Degenhard; Ulrich, Wolf-Ruediger
PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030769	A1	20050407	WO 2004-EP52376	20040930

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004276013	A1	20050407	AU 2004-276013	20040930
CA 2540242	A1	20050407	CA 2004-2540242	20040930
EP 1673371	A1	20060628	EP 2004-787261	20040930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1856494	A	20061101	CN 2004-80027819	20040930
BR 2004014873	A	20061212	BR 2004-14873	20040930
JP 2007507465	T	20070329	JP 2006-530262	20040930
NO 2006001316	A	20060323	NO 2006-1316	20060323
MX 2006PA03554	A	20060605	MX 2006-PA3554	20060329
IN 2006MN00473	A	20070316	IN 2006-MN473	20060424
PRIORITY APPLN. INFO.:			EP 2003-22064	A 20031001
			WO 2004-EP52376	W 20040930

OTHER SOURCE(S): CASREACT 142:373836; MARPAT 142:373836

GI



I



II

AB Title compds. I [R1 = alkoxy; A = alkylene; R2 = H, halo, alkyl, alkoxy; Het = (un)substituted monocyclic or fused 5-10 membered (un)saturated heteroaryl containing 1-3 heteroatoms selected from N, O, and S] and their resp. pharmaceutically acceptable salts, are prepared and disclosed as inducible no-synthase inhibitors. Thus, e.g., II was prepared via Suzuki coupling of 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine (preparation given) with 2-furanylboronic acid. The activity of I towards inducible NO-synthase was evaluated in inhibition assays and revealed -logIC50 values from 6.61 up to 7.61 mol/L. I as inducible NO-synthase inhibitors should prove useful in the treatment of acute and chronic inflammatory diseases.

IT 849356-71-4P 849356-72-5P 849356-73-6P
849356-74-7P 849356-75-8P 849356-76-9P
849356-77-0P 849356-78-1P 849356-79-2P
849356-80-5P 849356-81-6P 849356-82-7P
849356-83-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyridine derivs. as inducible NO-synthase inhibitors)

RN 849356-71-4 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 6-(2-furanyl)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 849356-72-5 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 6-(3-furanyl)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 849356-73-6 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 849356-74-7 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 849356-75-8 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 849356-76-9 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 6-(1H-indol-5-yl)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 849356-77-0 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 6-(1H-benzimidazol-2-yl)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 849356-78-1 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(5-methyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 849356-79-2 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 6-benzo[b]thien-3-yl-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 849356-80-5 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 6-(2-benzofuranyl)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 849356-81-6 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 6-benzo[b]thien-2-yl-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 849356-82-7 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)



RN 849356-83-8 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(5-phenyl-2-thienyl)- (9CI) (CA INDEX NAME)



IT 608880-54-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazopyridine derivs. as inducible NO-synthase inhibitors)
RN 608880-54-2 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 6-iodo-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:300444 CAPLUS
DOCUMENT NUMBER: 142:373835
TITLE: Preparation of imidazopyridine derivatives as inducible NO-synthase inhibitors
INVENTOR(S): Boer, Rainer; Ulrich, Wolf-Ruediger; Eltze, Manfrid; Marx, Degenhard; Graedler, Ulrich; Fuchss, Thomas
PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030768	A1	20050407	WO 2004-EP52370	20040930
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004276012	A1	20050407	AU 2004-276012	20040930
CA 2540239	A1	20050407	CA 2004-2540239	20040930
EP 1675853	A1	20060705	EP 2004-787257	20040930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1856492	A	20061101	CN 2004-80027796	20040930
BR 2004015038	A	20061212	BR 2004-15038	20040930
JP 2007507463	T	20070329	JP 2006-530260	20040930
NO 2006001343	A	20060324	NO 2006-1343	20060324
MX 2006PA03347	A	20060608	MX 2006-PA3347	20060324
US 2007010549	A1	20070111	US 2006-573203	20060324
IN 2006MN00474	A	20070817	IN 2006-MN474	20060424
PRIORITY APPLN. INFO.:			EP 2003-22042 A	20031001
			WO 2004-EP52370 W	20040930

OTHER SOURCE(S): CASREACT 142:373835; MARPAT 142:373835
GI



I



II

AB Title compds. I [R1 = H, alkyl; R2 = H, halo, OH, etc.; R3 = H, halo, alkyl, alkoxy; R4 = alkyl; R5 = alkyl] and their resp. pharmaceutically acceptable salts, are prepared and disclosed as inducible no-synthase inhibitors. Thus, e.g., II was prepared via Wittig reaction of triphenyl-{1-(3H-imidazo[4,5-b]pyridin-2-yl)-propyl}-phosphonium chloride (preparation given) with 4-methoxypyridine-2-carboxaldehyde and subsequent hydrogenation. The activity of II towards inducible NO-synthase was evaluated in an inhibition assay and revealed a -logIC50 value of 7.15 mol/L. I as inducible NO-synthase inhibitors should prove useful in the treatment of acute and chronic inflammatory diseases.

IT 849346-44-7P 849346-45-8P 849346-46-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyridine derivs. as inducible NO-synthase inhibitors)

RN 849346-44-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)-1-methylethyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 849346-45-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[1-[(4-methoxy-2-pyridinyl)methyl]propyl]- (9CI) (CA INDEX NAME)



RN 849346-46-9 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)



IT 849346-55-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazopyridine derivs. as inducible NO-synthase inhibitors)
RN 849346-55-0 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)-1-methylethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:777790 CAPLUS
DOCUMENT NUMBER: 139:292156
TITLE: Preparation of alkoxypyridines as inducible nitric oxide synthase (iNOS) inhibitors
INVENTOR(S): Boer, Rainer; Marx, Degenhard; Eltze, Manfrid; Klein, Thomas; Nave, Ruediger; Graedler, Ulrich; Fuchss, Thomas; Barsig, Johannes; Ulrich, Wolf-Ruediger
PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080607	A1	20031002	WO 2003-EP3076	20030325

W: AE, AL, AU, BA, BR, CA, CN, CO, CU, DZ, EC, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US, VN, YU, ZA, ZW
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,

SI, SK, TR

CA 2480385	A1	20031002	CA 2003-2480385		20030325
AU 2003226706	A1	20031008	AU 2003-226706		20030325
EP 1490366	A1	20041229	EP 2003-744851		20030325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003008785	A	20050111	BR 2003-8785		20030325
CN 1642955	A	20050720	CN 2003-806917		20030325
JP 2005525388	T	20050825	JP 2003-578361		20030325
NZ 535959	A	20060526	NZ 2003-535959		20030325
IN 2004MN00462	A	20050218	IN 2004-MN462		20040820
MX 2004PA09283	A	20050125	MX 2004-PA9283		20040923
US 2005171125	A1	20050804	US 2004-509396		20040924
US 7138399	B2	20061121			
ZA 2004007766	A	20060628	ZA 2004-7766		20040927
NO 2004004633	A	20041223	NO 2004-4633		20041027
PRIORITY APPLN. INFO.:			EP 2002-7049	A	20020327
			WO 2003-EP3076	W	20030325

OTHER SOURCE(S): MARPAT 139:292156

GI



I



II

AB Title compds. I [wherein R1 = alkoxy; A = alkylene; B = (un)substituted 3H-imidazo[4,5-b]pyridin-2-yl, 9H-purin-8-yl; their salts, N-oxides, and salts of the N-oxides] were prepared as inducible NO-synthase (iNOS) inhibitor for treatment of acute inflammatory diseases and chronic inflammatory diseases of peripheral organs and central nervous system (CNS). For example, II (m.p. = 116-117°) was prepared by cyclocondensation of Me 3-(4-methoxypyridin-2-yl)propionate (preparation given) with 2,3-diaminopyridine in the presence of polyphosphoric acid at 160° for 1 h. Selected invention compds. inhibited iNOS with -logIC50 (M) in the range of 7.03-7.55. Thus, I and their pharmaceutical compns. are useful for treating acute inflammatory diseases, chronic inflammatory diseases of peripheral organs and CNS and cancer (no data).

IT 608880-48-4P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-3H-imidazo[4,5-b]pyridine 608880-53-1P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-bromo-3H-imidazo[4,5-b]pyridine 608880-54-2P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine 608880-74-6P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(4-aminophenyl)-3H-imidazo[4,5-b]pyridine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(inducible NO-synthase inhibitor; preparation of alkoxypyridines as inducible NO-synthase inhibitors)

RN 608880-48-4 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 608880-53-1 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 6-bromo-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 608880-54-2 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 6-iodo-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 608880-74-6 CAPLUS
CN Benzenamine, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



IT 608880-50-8P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-7-methyl-3H-imidazo[4,5-b]pyridine 608880-51-9P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-5,7-dimethyl-3H-imidazo[4,5-b]pyridine 608880-52-0P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-5-methoxy-3H-imidazo[4,5-b]pyridine 608880-55-3P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-nitro-3H-imidazo[4,5-b]pyridine 608880-56-4P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-trifluoromethyl-3H-imidazo[4,5-b]pyridine 608880-57-5P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-phenyl-3H-imidazo[4,5-b]pyridine 608880-58-6P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-methyl-3H-imidazo[4,5-b]pyridine 608880-59-7P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(2-methylpropyl)-3H-imidazo[4,5-b]pyridine 608880-60-0P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-cyclohexylmethyl-3H-imidazo[4,5-b]pyridine 608880-61-1P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(2-phenylethyl)-3H-imidazo[4,5-

b]pyridine 608880-62-2P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(3,4-dichlorophenyl)-3H-imidazo[4,5-b]pyridine 608880-63-3P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(4-bromophenyl)-3H-imidazo[4,5-b]pyridine 608880-64-4P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(4-bromobenzyl)-3H-imidazo[4,5-b]pyridine 608880-65-5P, 7-(2-Methoxyethoxy)-2-[2-(4-methoxypyridin-2-yl)ethyl]-3H-imidazo[4,5-b]pyridine 608880-66-6P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-7-(2-phenylethoxy)-3H-imidazo[4,5-b]pyridine 608880-67-7P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-7-(2,2,2-trifluoroethoxy)-3H-imidazo[4,5-b]pyridine 608880-68-8P, 7-Hydroxy-2-[2-(4-methoxypyridin-2-yl)ethyl]-3H-imidazo[4,5-b]pyridine 608880-69-9P , 2-[2-(4-Methoxypyridin-2-yl)ethyl]-7-(2-p-tolylethyl)-3H-imidazo[4,5-b]pyridine 608880-70-2P, 2,7-Bis[2-(4-methoxypyridin-2-yl)ethyl]-3H-imidazo[4,5-b]pyridine 608880-71-3P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-7-[2-(2-pyridyl)ethyl]-3H-imidazo[4,5-b]pyridine 608880-72-4P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-p-tolyl-3H-imidazo[4,5-b]pyridine 608880-73-5P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(pyridin-3-yl)-3H-imidazo[4,5-b]pyridine 608880-75-7P , 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(4-hydroxyphenyl)-3H-imidazo[4,5-b]pyridine 608880-76-8P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-[4-(N,N-dimethylamino)phenyl]-3H-imidazo[4,5-b]pyridine 608880-77-9P , 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(4-trifluoromethylphenyl)-3H-imidazo[4,5-b]pyridine 608880-78-0P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(3,4-dimethoxyphenyl)-3H-imidazo[4,5-b]pyridine 608880-79-1P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(4-benzyloxyphenyl)-3H-imidazo[4,5-b]pyridine 608880-80-4P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(4-benzyloxy-3-fluorophenyl)-3H-imidazo[4,5-b]pyridine 608880-81-5P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(4-cyanophenyl)-3H-imidazo[4,5-b]pyridine 608880-82-6P , 2-[2-(4-Methoxypyridin-2-yl)ethyl]-3H-imidazo[4,5-b]pyridine-6-carboxylic acid methyl ester 608880-83-7P, N-[4-[2-[2-(4-Methoxypyridin-2-yl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]phenyl]acetamide 608880-84-8P, N-[4-[2-[2-(4-Methoxypyridin-2-yl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]phenyl]benzenesulfonamide 608880-85-9P , 2-[2-(4-Methoxy-1-oxopyridin-2-yl)ethyl]-3H-imidazo[4,5-b]pyridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inducible NO-synthase inhibitor; preparation of alkoxypyridines as inducible NO-synthase inhibitors)

RN 608880-50-8 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-7-methyl- (9CI) (CA INDEX NAME)



RN 608880-51-9 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-5,7-dimethyl- (9CI) (CA INDEX NAME)



RN 608880-52-0 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 608880-55-3 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-nitro- (9CI) (CA INDEX NAME)



RN 608880-56-4 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 608880-57-5 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 608880-58-6 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 608880-59-7 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 608880-60-0 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 6-(cyclohexylmethyl)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 608880-61-1 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 608880-62-2 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 6-(3,4-dichlorophenyl)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 608880-63-3 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 6-(4-bromophenyl)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 608880-64-4 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 6-[(4-bromophenyl)methyl]-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 608880-65-5 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 7-(2-methoxyethoxy)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 608880-66-6 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-7-(2-phenylethoxy)- (9CI) (CA INDEX NAME)



RN 608880-67-7 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)



RN 608880-68-8 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-7-ol, 2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 608880-69-9 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-7-[2-(4-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 608880-70-2 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2,7-bis[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 608880-71-3 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-7-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 608880-72-4 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 608880-73-5 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 608880-75-7 CAPLUS
CN Phenol, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 608880-76-8 CAPLUS
CN Benzenamine, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 608880-77-9 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 608880-78-0 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 6-(3,4-dimethoxyphenyl)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 608880-79-1 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 608880-80-4 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 6-[3-fluoro-4-(phenylmethoxy)phenyl]-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 608880-81-5 CAPLUS
CN Benzonitrile, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 608880-82-6 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine-6-carboxylic acid, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 608880-83-7 CAPLUS
CN Acetamide, N-[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 608880-84-8 CAPLUS
CN Benzenesulfonamide, N-[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 608880-85-9 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-1-oxido-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 07:37:29 ON 12 OCT 2007)

FILE 'REGISTRY' ENTERED AT 07:37:34 ON 12 OCT 2007
L1 STRUCTURE UPLOADED
L2 5 S L1
L3 133 S L1 FULL

FILE 'CAPLUS' ENTERED AT 07:38:01 ON 12 OCT 2007
L4 7 S L3 FULL

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	39.71	212.02

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.46	-5.46

STN INTERNATIONAL LOGOFF AT 07:41:44 ON 12 OCT 2007